Nuevolution develops tablet-based drugs using its tried-and-tested, patented technology platform Chemetics® – on both a proprietary basis and on assignment from global pharmaceutical companies. Chemetics® enables DNA-coded synthesis and evaluation against selected biological target structures of up to a million times more substances than the screening methods traditionally used today by global pharmaceutical companies. It also facilitates optimization of the most attractive molecules. The method saves time and money, while increasing the potential to identify suitable candidate drugs.
Nuevolution’s pipeline comprises in excess of ten projects targeting cancer and inflammatory diseases and the company has already generated hundreds of million Swedish kronor through its partnerships with leading global pharmaceutical companies. The project that is most advanced is targeted at ROR-γ, an extremely attractive target structure for the treatment of such chronic inflammatory diseases as multiple sclerosis, rheumatism and psoriasis.
The company was founded in 2001 and its shares are traded on Nasdaq First North Premier.